Impact of a transient instability of the ecstasy market on health concerns and drug use patterns in The Netherlands

International Journal of Drug Policy

Volumn 23, Issue 2, 2012, Pages 134-140

  Brunt, Tibor M ^a   Niesink, Raymond J M ^a   van den Brink, Wim ^b  

^a NETHERLANDS INSTITUTE OF MENTAL HEALTH AND ADDICTION   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Drug use patterns; Ecstasy; Health concerns; Time series

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 HYDROXYBUTYRIC ACID; COCAINE;

ALCOHOLISM; ARTICLE; ATTITUDE TO HEALTH; COCAINE DEPENDENCE; CONTROLLED STUDY; DRUG ABUSE PATTERN; DRUG LEGISLATION; DRUG MARKETING; DRUG MISUSE; DRUG PROGRAM; DRUG SCREENING; DRUG TRAFFIC; HARM REDUCTION; HEALTH HAZARD; HUMAN; MULTIPLE DRUG ABUSE; NETHERLANDS; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; PUBLIC HEALTH SERVICE; RISK FACTOR;

EUROPEAN UNION; HALLUCINOGENS; HARM REDUCTION; HEALTH POLICY; HUMANS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NETHERLANDS; QUALITY CONTROL; SUBSTANCE-RELATED DISORDERS; TABLETS; TIME FACTORS;

EID: 84857797964     PISSN: 09553959     EISSN: 18734758     Source Type: Journal    
DOI: 10.1016/j.drugpo.2011.05.016     Document Type: Article

References (46)

1. Asbridge M., Weerasinghe S. Homicide in Chicago from 1890 to 1930: Prohibition and its impact on alcohol- and non-alcohol-related homicides. Addiction 2009, 104(3):355-364.
2. Benschop A., Rabes M., Korf D.J. Pill testing, ecstasy & prevention 2002, Rozenberg, Amsterdam, The Netherlands.
3. Bossong M., Brunt T.M., Van Dijk J.P., Rigter S., Hoek J., Goldschmidt H., et al. mCPP: An undesired addition to the ecstasy market. Journal of Psychopharmacology 2010, 24(9):1395-1401.
4. Box G.E.P., Jenkins G.M. Time series analysis: Forecasting and control 1976, Holden Day, San Francisco.
5. Box G.E.P., Tiao G.C. Intervention analysis with applications to economic and environmental problems. Journal of the American Statistical Association 1975, 70:70-79.
6. Brunt T.M., Poortman A., Niesink R.J., van den Brink W. Instability of the ecstasy market and a new kid on the block: Mephedrone. Journal of Psychopharmacology 2010, [Epub ahead of print].
7. Callaghan R.C., Cunningham J.K., Victor J.C., Liu L.M. Impact of Canadian federal methamphetamine precursor and essential chemical regulations on methamphetamine-related acute-care hospital admissions. Drug and Alcohol Dependence 2009, 105(3):185-193.
8. Caulkins J.P., Reuter P. Setting goals for drug policy: Harm reduction or use reduction?. Addiction 1997, 92(9):1143-1150.
9. Cole J.C., Goudie A.J., Field M., Loverseed A.C., Charlton S., Sumnall H.R. The effects of perceived quality on the behavioural economics of alcohol, amphetamine, cannabis, cocaine, and ecstasy purchases. Drug and Alcohol Dependence 2008, 94(1-3):183-190.
10. Cunningham J.K., Liu L.M. Impacts of federal ephedrine and pseudoephedrine regulations on methamphetamine-related hospital admissions. Addiction 2003, 98(9):1229-1237.
11. Cunningham J.K., Liu L.M. Impacts of federal precursor chemical regulations on methamphetamine arrests. Addiction 2005, 100(4):479-488.
12. Cunningham J.K., Liu L.M., Muramoto M. Methamphetamine suppression and route of administration: Precursor regulation impacts on snorting, smoking, swallowing and injecting. Addiction 2008, 103(7):1174-1186.
13. Edwards G. Time-series analysis as an important contemporary statistical tool. Addiction 2001, 96(7):941-942.
14. EMCDDA. (2010). European Monitoring Centre for Drugs and Drug Addiction, annual report 2010. Lissabon, Portugal: Official Publications European Communities. Available from Accessed 01.01.11. http://www.emcdda.europa.eu/attachements.cfm/att_120104_EN_EMCDDA_AR2010_EN.pdf.
15. Europol. (2007). Amphetamine-type stimulants in the European Union 1998-2007. Te Hague, The Netherlands. Available from Accessed 07.20.10. http://www.europol.europa.eu/publications/Serious_Crime_Overviews/EuropolUNGASSAssessment.PDF.
16. Gilmour S., Degenhardt L., Hall W., Day C. Using intervention time series analyses to assess the effects of imperfectly identifiable natural events: A general method and example. BMC Medical Research Methodology 2006, 6:16.
17. Goudie A.J., Sumnall H.R., Field M., Clayton H., Cole J.C. The effects of price and perceived quality on the behavioural economics of alcohol, amphetamine, cannabis, cocaine, and ecstasy purchases. Drug and Alcohol Dependence 2007, 89(2-3):107-115.
18. Gouzoulis-Mayfrank E., Daumann J. The confounding problem of polydrug use in recreational ecstasy/MDMA users: A brief overview. Journal of Psychopharmacology 2006, 20(2):188-193.
19. Grov C., Kelly B.C., Parsons J.T. Polydrug use among club-going young adults recruited through time-space sampling. Substance Use and Misuse 2009, 44(6):848-864.
20. Herttua K., Mäkelä P., Martikainen P. Changes in alcohol-related mortality and its socioeconomic differences after a large reduction in alcohol prices: A natural experiment based on register data. American Journal of Epidemiology 2008, 168(10):1110-1118.
21. Korf D.J., Benschop A., Brunt T.M. Pill testing in The Netherlands 2003, Rozenberg, Amsterdam, The Netherlands.
22. Koski A., Sirén R., Vuori E., Poikolainen K. Alcohol tax cuts and increase in alcohol-positive sudden deaths: A time-series intervention analysis. Addiction 2007, 102(3):362-368.
23. McCleary R., Hay R.A. Applied time series analysis for the social sciences 1980, Sage Publications, Beverly Hills, CA.
24. Medina K.L., Shear P.K. Anxiety, depression, and behavioral symptoms of executive dysfunction in ecstasy users: Contributions of polydrug use. Drug and Alcohol Dependence 2007, 87:303-311.
25. Milhazes N., Martins P., Uriarte E., Garrido J., Calheiros R., Marques M.P., et al. Electrochemical and spectroscopic characterisation of amphetamine-like drugs: Application to the screening of 3,4-methylenedioxymethamphetamine (MDMA) and its synthetic precursors. Analytica Chimica Acta 2007, 596(2):231-241.
26. Milliet Q., Weyermann C., Esseiva P. The profiling of MDMA tablets: A study of the combination of physical characteristics and organic impurities as sources of information. Forensic Science International 2009, 187(1-3):58-65.
27. Nutt D.J., King L.A., Phillips L.D. Drug harms in the UK: A multicriteria decision analysis. Lancet 2010, 376(9752):1558-1565. Independent Scientific Committee on Drugs.
28. Nutt D., King L.A., Saulsbury W., Blakemore C. Development of a rational scale to assess the harm of drugs of potential misuse. Lancet 2007, 369(9566):1047-1053.
29. Parrott A.C. Is ecstasy MDMA? A review of the proportion of ecstasy tablets containing MDMA, their dosage levels, and the changing perceptions of purity. Psychopharmacology 2004, 173(3-4):234-241.
30. Parrott A.C., Milani R., Parmar R., Turner J.J.D. Ecstasy polydrug users and other recreational drug users in Britain and Italy: Psychiatric symptoms and psychobiological problems. Psychopharmacology 2001, 159(1):77-82.
31. Roxburgh A., Degenhardt L., Breen C. Changes in patterns of drug use among injecting drug users following changes in the availability of heroin in New South Wales, Australia. Drug and Alcohol Review 2004, 23(3):287-294.
32. Shadish W.R., Cook T.D., Campbell D.T. Experimental and quasi-experimental designs for generalized causal inference 2002, Houghton Mifflin, Boston, MA.
33. Smithson M., McFadden M., Mwesigye S.E. Impact of Federal drug law enforcement on the supply of heroin in Australia. Addiction 2005, 100(8):1110-1120.
34. Spruit I.P. Monitoring synthetic drug markets, trends, and public health. Substance Use and Misuse 2001, 36(1-2):23-47.
35. Sumnall H.R., Tyler E., Wagstaff G.F., Cole J.C.A. Behavioural economic analysis of alcohol, amphetamine, cocaine and ecstasy purchases by polysubstance misusers. Drug and Alcohol Dependence 2004, 76(1):93-99.
36. Tanner-Smith E.E Pharmacological content of tablets sold as " ecstasy": Results from an online testing service. Drug and Alcohol Dependence 2006, 83(3):247-254.
37. Taylor, W. (2000). A pattern test for distinguishing between autoregressive and mean-shift data. Available from Accessed 10.03.10. http://www.variation.com/cpa/tech/pattern.html.
38. Topp L., Day C., Degenhardt L. Changes in patterns of drug injection concurrent with a sustained reduction in the availability of heroin in Australia. Drug and Alcohol Dependence 2003, 70(3):275-286.
39. UNODC. (2010). United Nations Office on Drugs and Crime. World drug report 2010. Vienna, Austria: United Nations. Available from Accessed 10.21.10. http://www.unodc.org/documents/wdr/WDR_2010/World_Drug_Report_2010_lo-res.pdf.
40. Van Amsterdam J., Opperhuizen A., Koeter M., van den Brink W. Ranking the harm of alcohol, tobacco and illicit drugs for the individual and the population. European Addiction Research 2010, 16(4):202-207.
41. Van Laar M.W., Cruts A.A.N., van Ooyen-Houben M.M.J., Meijer R.F., Brunt T.M. The Netherlands National Drug Monitor: Annual report 2009 2010, Trimbos Institute, Utrecht, The Netherlands.
42. Vogels N., Brunt T.M., Rigter S., van Dijk P., Vervaeke H., Niesink R.J. Content of ecstasy in the Netherlands: 1993-2008. Addiction 2009, 104(12):2057-2066.
43. Weatherburn D. Dilemmas in harm minimization. Addiction 2009, 104(3):335-339.
44. Weatherburn D., Jones C., Freeman K., Makkai T. Supply control and harm reduction: Lessons from the Australian heroin 'drought'. Addiction 2003, 98(1):83-91.
45. Wood E., Stoltz J., Li K., Montaner J., Kerr T. Changes in Canadian heroin supply coinciding with the Australian heroin shortage. Addiction 2006, 101(5):689-695.
46. Wu L.T., Parrott A.C., Ringwalt C.L., Yang C., Blazer D.G. The variety of ecstasy/MDMA users: Results from the National Epidemiologic Survey on alcohol and related conditions. The American Journal on Addictions 2009, 18(6):452-461.